PAPP stands for Pregnancy-Associated Plasma Protein. It is a term used in the field of medicine and obstetrics to refer to a specific blood protein that is produced by the placenta during pregnancy. This protein, also known as PAPP-A, plays a crucial role in the biological processes that occur during pregnancy.
PAPP-A is primarily secreted by the syncytiotrophoblasts, which are specialized cells found in the placenta. It is considered a marker for early detection and assessment of some pregnancy-related complications, such as chromosomal abnormalities and fetal growth disorders.
In clinical practice, PAPP-A levels are often measured during the first trimester of pregnancy as part of prenatal screening tests, such as the combined first-trimester screening or the integrated test. Abnormal levels of PAPP-A can indicate an increased risk of certain conditions, such as Down syndrome and preeclampsia.
Additionally, PAPP-A has also shown potential in predicting adverse outcomes in cardiovascular diseases and acute coronary syndromes, where its concentrations in the blood can provide insights into the severity and prognosis of such conditions.
Overall, PAPP is a significant biomarker that aids healthcare professionals in the assessment and management of various pregnancy-related complications and potentially other health conditions. Its measurement and interpretation contribute to early detection, risk evaluation, and appropriate planning for appropriate medical interventions during pregnancy and beyond.
